Business Context and Reporting Period
This Form 8-K Current Report is filed by Cartesian Therapeutics, Inc. (RNAC) for the reporting period ending May 22, 2026. The filing discloses the entry into a material definitive loan agreement and the resignation of a senior executive officer.
Key Financial Metrics and Debt Structure
The Company entered into a Loan and Security Agreement providing for senior secured term loans with an aggregate principal amount of up to $150.0 million. The structure includes:
- Tranche 1: $50.0 million funded immediately on the closing date.
- Tranche 2: $25.0 million available between January 1, 2027, and December 1, 2027, contingent on clinical and financing milestones.
- Tranche 3: $25.0 million available between January 1, 2028, and June 1, 2028, contingent on approval and sales milestones.
- Tranche 4: Up to $50.0 million available at the Lenders' sole discretion.
Loan Terms:
- Maturity: June 1, 2030.
- Interest Rate: Variable, equal to the greater of 8.95% or the prime rate plus 2.20%.
- Amortization: Monthly principal and interest payments commence July 1, 2029.
- Conversion Rights: Lenders may convert up to $15.0 million of principal into common stock at a price of $8.2526 per share (or lower effective price in a qualifying financing), subject to a 9.985% beneficial ownership cap.
- Collateral: First priority security interest in substantially all assets, excluding intellectual property.
Financial Covenants:
- Cash Covenant: Commencing April 1, 2027, if market capitalization is under $750.0 million, the Company must maintain unrestricted cash equal to at least 80% of outstanding obligations (reducible to 50% upon achievement of Tranche 2 milestones).
- Revenue Covenant: Commencing January 1, 2029, a minimum trailing three-month net product revenue of $40.0 million with required quarter-over-quarter growth.
The filing does not provide current revenue, profit, cash flow, or liquidity figures as of the reporting date.
Material Changes and Personnel Updates
Executive Departure: On May 22, 2026, Milos Miljkovic, M.D., resigned as Chief Medical Officer. His employment is expected to cease on May 31, 2026. The Company anticipates entering into a separation agreement providing six months' salary, a pro-rated bonus, and up to six months of COBRA coverage.
Capital Structure Change: The Company has incurred a new direct financial obligation of up to $150.0 million, significantly altering its debt profile and introducing equity conversion risks.
Outlook, Risks, and Contingencies
Operational Risks: Access to the remaining $100.0 million of the loan facility is contingent upon the achievement of specific clinical, regulatory, and sales milestones. Failure to meet these milestones will prevent the drawdown of Tranches 2 and 3.
Financial Risks: The Company faces strict financial covenants starting in 2027 regarding cash reserves and product revenue. Breach of these covenants could trigger events of default. Additionally, the variable interest rate exposes the Company to rising rate environments.
Dilution Risk: Lenders hold the right to convert debt into equity, which could result in dilution to existing shareholders, capped at 19.99% of the outstanding common stock as of the closing date.
Key Facts for Investor Verification
- Verify the Company's current unrestricted cash balance against the 80% covenant requirement effective April 1, 2027.
- Confirm the status of clinical and regulatory milestones required to unlock the $50.0 million in milestone-based tranches.
- Monitor the Company's ability to generate $40.0 million in trailing three-month net product revenue by January 2029.
- Review the potential dilution impact if lenders exercise their conversion rights on the $15.0 million convertible portion.
- Assess the impact of the Chief Medical Officer's departure on ongoing clinical programs and pipeline execution.